Linked Life Data

16536458

Source:http://linkedlifedata.com/resource/pubmed/id/16536458

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:16536458rdf:typepubmed:Citationlld:pubmed
pubmed-article:16536458lifeskim:mentionsumls-concept:C0010453lld:lifeskim
pubmed-article:16536458lifeskim:mentionsumls-concept:C2717940lld:lifeskim
pubmed-article:16536458lifeskim:mentionsumls-concept:C0085104lld:lifeskim
pubmed-article:16536458lifeskim:mentionsumls-concept:C0599894lld:lifeskim
pubmed-article:16536458lifeskim:mentionsumls-concept:C1450054lld:lifeskim
pubmed-article:16536458lifeskim:mentionsumls-concept:C1521840lld:lifeskim
pubmed-article:16536458lifeskim:mentionsumls-concept:C1723263lld:lifeskim
pubmed-article:16536458lifeskim:mentionsumls-concept:C0071444lld:lifeskim
pubmed-article:16536458pubmed:issue2lld:pubmed
pubmed-article:16536458pubmed:dateCreated2006-3-15lld:pubmed
pubmed-article:16536458pubmed:abstractTextThe study was to develop paclitaxel-loaded formulations using a novel type of self-assembled nanoparticles that was composed of block copolymers synthesized from poly(gamma-glutamic acid) and poly(lactide) via a simple coupling reaction. The nanoparticles (the NPs) were prepared with various feed weight ratios of paclitaxel to block copolymer (the P/BC ratio). The morphology of all prepared nanoparticles was spherical and the surfaces were smooth. Increasing the P/BC ratio significantly increased the drug loading content of the prepared nanoparticles, but remarkably reduced the drug loading efficiency. The release rate of paclitaxel from the NPs decreased significantly as the P/BC ratio increased. For the potential of targeting liver cancer cells, galactosamine was further conjugated on the prepared nanoparticles (the Gal-NPs) as a targeting moiety. It was found that the activity in inhibiting the growth of HepG2 cells (a liver cancer cell line) by the Gal-NPs was comparable to that of a clinically available paclitaxel formulation, while the NPs displayed a significantly less activity. This may be attributed to the fact that the Gal-NPs had a specific interaction with HepG2 cells via ligand-receptor recognition. Cells treated with distinct paclitaxel formulations resulted in arrest in the G2/M phase. The arrest of cells in the G2/M phase was highly suggestive of interference by paclitaxel with spindle formation and was consistent with the morphological findings presented herein. In conclusion, the active targeting nature of the Gal-NPs prepared in the study may be used as a potential drug delivery system for the targeted delivery to liver cancers.lld:pubmed
pubmed-article:16536458pubmed:languageenglld:pubmed
pubmed-article:16536458pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16536458pubmed:citationSubsetIMlld:pubmed
pubmed-article:16536458pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16536458pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16536458pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16536458pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16536458pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16536458pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16536458pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16536458pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16536458pubmed:statusMEDLINElld:pubmed
pubmed-article:16536458pubmed:issn1043-1802lld:pubmed
pubmed-article:16536458pubmed:authorpubmed-author:LiangHsiang-F...lld:pubmed
pubmed-article:16536458pubmed:authorpubmed-author:SungHsing-Wen...lld:pubmed
pubmed-article:16536458pubmed:authorpubmed-author:ChenChiung-To...lld:pubmed
pubmed-article:16536458pubmed:authorpubmed-author:LeePo-WeiPWlld:pubmed
pubmed-article:16536458pubmed:authorpubmed-author:ChenSung-Chin...lld:pubmed
pubmed-article:16536458pubmed:authorpubmed-author:ChenMei-ChinM...lld:pubmed
pubmed-article:16536458pubmed:issnTypePrintlld:pubmed
pubmed-article:16536458pubmed:volume17lld:pubmed
pubmed-article:16536458pubmed:ownerNLMlld:pubmed
pubmed-article:16536458pubmed:authorsCompleteYlld:pubmed
pubmed-article:16536458pubmed:pagination291-9lld:pubmed
pubmed-article:16536458pubmed:dateRevised2008-11-21lld:pubmed
pubmed-article:16536458pubmed:meshHeadingpubmed-meshheading:16536458...lld:pubmed
pubmed-article:16536458pubmed:meshHeadingpubmed-meshheading:16536458...lld:pubmed
pubmed-article:16536458pubmed:meshHeadingpubmed-meshheading:16536458...lld:pubmed
pubmed-article:16536458pubmed:meshHeadingpubmed-meshheading:16536458...lld:pubmed
pubmed-article:16536458pubmed:meshHeadingpubmed-meshheading:16536458...lld:pubmed
pubmed-article:16536458pubmed:meshHeadingpubmed-meshheading:16536458...lld:pubmed
pubmed-article:16536458pubmed:meshHeadingpubmed-meshheading:16536458...lld:pubmed
pubmed-article:16536458pubmed:meshHeadingpubmed-meshheading:16536458...lld:pubmed
pubmed-article:16536458pubmed:meshHeadingpubmed-meshheading:16536458...lld:pubmed
pubmed-article:16536458pubmed:meshHeadingpubmed-meshheading:16536458...lld:pubmed
pubmed-article:16536458pubmed:meshHeadingpubmed-meshheading:16536458...lld:pubmed
pubmed-article:16536458pubmed:articleTitlePaclitaxel-loaded poly(gamma-glutamic acid)-poly(lactide) nanoparticles as a targeted drug delivery system against cultured HepG2 cells.lld:pubmed
pubmed-article:16536458pubmed:affiliationDepartment of Chemical Engineering, National Tsing Hua University, Hsinchu, Taiwan, ROC.lld:pubmed
pubmed-article:16536458pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:16536458pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed